347 related articles for article (PubMed ID: 32719455)
1. Molecular subtyping and genomic profiling expand precision medicine in refractory metastatic triple-negative breast cancer: the FUTURE trial.
Jiang YZ; Liu Y; Xiao Y; Hu X; Jiang L; Zuo WJ; Ma D; Ding J; Zhu X; Zou J; Verschraegen C; Stover DG; Kaklamani V; Wang ZH; Shao ZM
Cell Res; 2021 Feb; 31(2):178-186. PubMed ID: 32719455
[TBL] [Abstract][Full Text] [Related]
2. Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple-negative breast cancer (IMpassion130): updated efficacy results from a randomised, double-blind, placebo-controlled, phase 3 trial.
Schmid P; Rugo HS; Adams S; Schneeweiss A; Barrios CH; Iwata H; Diéras V; Henschel V; Molinero L; Chui SY; Maiya V; Husain A; Winer EP; Loi S; Emens LA;
Lancet Oncol; 2020 Jan; 21(1):44-59. PubMed ID: 31786121
[TBL] [Abstract][Full Text] [Related]
3. Subtyping-based platform guides precision medicine for heavily pretreated metastatic triple-negative breast cancer: The FUTURE phase II umbrella clinical trial.
Liu Y; Zhu XZ; Xiao Y; Wu SY; Zuo WJ; Yu Q; Cao AY; Li JJ; Yu KD; Liu GY; Wu J; Sun T; Cui JW; Lv Z; Li HP; Zhu XY; Jiang YZ; Wang ZH; Shao ZM
Cell Res; 2023 May; 33(5):389-402. PubMed ID: 36973538
[TBL] [Abstract][Full Text] [Related]
4. Nab-paclitaxel for the treatment of triple-negative breast cancer: Rationale, clinical data and future perspectives.
Schettini F; Giuliano M; De Placido S; Arpino G
Cancer Treat Rev; 2016 Nov; 50():129-141. PubMed ID: 27665540
[TBL] [Abstract][Full Text] [Related]
5. Atezolizumab Plus nab-Paclitaxel in the Treatment of Metastatic Triple-Negative Breast Cancer With 2-Year Survival Follow-up: A Phase 1b Clinical Trial.
Adams S; Diamond JR; Hamilton E; Pohlmann PR; Tolaney SM; Chang CW; Zhang W; Iizuka K; Foster PG; Molinero L; Funke R; Powderly J
JAMA Oncol; 2019 Mar; 5(3):334-342. PubMed ID: 30347025
[TBL] [Abstract][Full Text] [Related]
6. Famitinib with Camrelizumab and Nab-Paclitaxel for Advanced Immunomodulatory Triple-Negative Breast Cancer (FUTURE-C-Plus): An Open-Label, Single-Arm, Phase II Trial.
Chen L; Jiang YZ; Wu SY; Wu J; Di GH; Liu GY; Yu KD; Fan L; Li JJ; Hou YF; Hu Z; Chen CM; Huang XY; Cao AY; Hu X; Zhao S; Ma XY; Xu Y; Sun XJ; Chai WJ; Guo X; Chen X; Xu Y; Zhu XY; Zou JJ; Yang WT; Wang ZH; Shao ZM
Clin Cancer Res; 2022 Jul; 28(13):2807-2817. PubMed ID: 35247906
[TBL] [Abstract][Full Text] [Related]
7. Tumor immune microenvironment and genomic evolution in a patient with metastatic triple negative breast cancer and a complete response to atezolizumab.
Molinero L; Li Y; Chang CW; Maund S; Berg M; Harrison J; Fassò M; O'Hear C; Hegde P; Emens LA
J Immunother Cancer; 2019 Oct; 7(1):274. PubMed ID: 31647026
[TBL] [Abstract][Full Text] [Related]
8. Combined angiogenesis and PD-1 inhibition for immunomodulatory TNBC: concept exploration and biomarker analysis in the FUTURE-C-Plus trial.
Wu SY; Xu Y; Chen L; Fan L; Ma XY; Zhao S; Song XQ; Hu X; Yang WT; Chai WJ; Guo XM; Chen XZ; Xu YH; Zhu XY; Zou JJ; Wang ZH; Jiang YZ; Shao ZM
Mol Cancer; 2022 Mar; 21(1):84. PubMed ID: 35337339
[TBL] [Abstract][Full Text] [Related]
9. Association of Immunophenotype With Pathologic Complete Response to Neoadjuvant Chemotherapy for Triple-Negative Breast Cancer: A Secondary Analysis of the BrighTNess Phase 3 Randomized Clinical Trial.
Filho OM; Stover DG; Asad S; Ansell PJ; Watson M; Loibl S; Geyer CE; Bae J; Collier K; Cherian M; O'Shaughnessy J; Untch M; Rugo HS; Huober JB; Golshan M; Sikov WM; von Minckwitz G; Rastogi P; Maag D; Wolmark N; Denkert C; Symmans WF
JAMA Oncol; 2021 Apr; 7(4):603-608. PubMed ID: 33599688
[TBL] [Abstract][Full Text] [Related]
10. Phase II Trial of Neoadjuvant Carboplatin and Nab-Paclitaxel in Patients with Triple-Negative Breast Cancer.
Yuan Y; Lee JS; Yost SE; Li SM; Frankel PH; Ruel C; Schmolze D; Robinson K; Tang A; Martinez N; Stewart D; Waisman J; Kruper L; Jones V; Menicucci A; Uygun S; Yoder E; van der Baan B; Yim JH; Yeon C; Somlo G; Mortimer J
Oncologist; 2021 Mar; 26(3):e382-e393. PubMed ID: 33098195
[TBL] [Abstract][Full Text] [Related]
11. Molecular Subtyping of Triple-Negative Breast Cancers by Immunohistochemistry: Molecular Basis and Clinical Relevance.
Zhao S; Ma D; Xiao Y; Li XM; Ma JL; Zhang H; Xu XL; Lv H; Jiang WH; Yang WT; Jiang YZ; Zhang QY; Shao ZM
Oncologist; 2020 Oct; 25(10):e1481-e1491. PubMed ID: 32406563
[TBL] [Abstract][Full Text] [Related]
12. Neoadjuvant atezolizumab in combination with sequential nab-paclitaxel and anthracycline-based chemotherapy versus placebo and chemotherapy in patients with early-stage triple-negative breast cancer (IMpassion031): a randomised, double-blind, phase 3 trial.
Mittendorf EA; Zhang H; Barrios CH; Saji S; Jung KH; Hegg R; Koehler A; Sohn J; Iwata H; Telli ML; Ferrario C; Punie K; Penault-Llorca F; Patel S; Duc AN; Liste-Hermoso M; Maiya V; Molinero L; Chui SY; Harbeck N
Lancet; 2020 Oct; 396(10257):1090-1100. PubMed ID: 32966830
[TBL] [Abstract][Full Text] [Related]
13. Serial single-cell profiling analysis of metastatic TNBC during Nab-paclitaxel and pembrolizumab treatment.
Deng J; Thennavan A; Shah S; Bagdatlioglu E; Klar N; Heguy A; Marier C; Meyn P; Zhang Y; Labbe K; Almonte C; Krogsgaard M; Perou CM; Wong KK; Adams S
Breast Cancer Res Treat; 2021 Jan; 185(1):85-94. PubMed ID: 32949350
[TBL] [Abstract][Full Text] [Related]
14. Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer.
Schmid P; Adams S; Rugo HS; Schneeweiss A; Barrios CH; Iwata H; Diéras V; Hegg R; Im SA; Shaw Wright G; Henschel V; Molinero L; Chui SY; Funke R; Husain A; Winer EP; Loi S; Emens LA;
N Engl J Med; 2018 Nov; 379(22):2108-2121. PubMed ID: 30345906
[TBL] [Abstract][Full Text] [Related]
15. Combined Targeted Therapies for First-line Treatment of Metastatic Triple Negative Breast Cancer-A Phase II Trial of Weekly Nab-Paclitaxel and Bevacizumab Followed by Maintenance Targeted Therapy With Bevacizumab and Erlotinib.
Symonds L; Linden H; Gadi V; Korde L; Rodler E; Gralow J; Redman M; Baker K; Wu QV; Jenkins I; Kurland B; Garrison M; Smith J; Anderson J; Van Haelst C; ; Specht J
Clin Breast Cancer; 2019 Apr; 19(2):e283-e296. PubMed ID: 30737173
[TBL] [Abstract][Full Text] [Related]
16. Combined atezolizumab and nab-paclitaxel in the treatment of triple negative breast cancer: a meta-analysis on their efficacy and safety.
Sharmni Vishnu K; Win TT; Aye SN; Basavaraj AK
BMC Cancer; 2022 Nov; 22(1):1139. PubMed ID: 36335316
[TBL] [Abstract][Full Text] [Related]
17. A Randomized Phase II Neoadjuvant Study of Cisplatin, Paclitaxel With or Without Everolimus in Patients with Stage II/III Triple-Negative Breast Cancer (TNBC): Responses and Long-term Outcome Correlated with Increased Frequency of DNA Damage Response Gene Mutations, TNBC Subtype, AR Status, and Ki67.
Jovanović B; Mayer IA; Mayer EL; Abramson VG; Bardia A; Sanders ME; Kuba MG; Estrada MV; Beeler JS; Shaver TM; Johnson KC; Sanchez V; Rosenbluth JM; Dillon PM; Forero-Torres A; Chang JC; Meszoely IM; Grau AM; Lehmann BD; Shyr Y; Sheng Q; Chen SC; Arteaga CL; Pietenpol JA
Clin Cancer Res; 2017 Aug; 23(15):4035-4045. PubMed ID: 28270498
[No Abstract] [Full Text] [Related]
18. Phase II trail of nab-paclitaxel in metastatic breast cancer patients with visceral metastases.
Xie Y; Gong C; Zhang J; Wang L; Cao J; Tao Z; Li T; Zhao Y; Li Y; Hu S; Wang B; Hu X
BMC Cancer; 2021 Nov; 21(1):1174. PubMed ID: 34727875
[TBL] [Abstract][Full Text] [Related]
19. A phase II clinical trial of weekly paclitaxel and carboplatin in combination with panitumumab in metastatic triple negative breast cancer.
Cowherd S; Miller LD; Melin SA; Akman S; Isom S; Cole J; Pullikuth A; Lawrence JA
Cancer Biol Ther; 2015; 16(5):678-83. PubMed ID: 25928118
[TBL] [Abstract][Full Text] [Related]
20. TBCRC 019: A Phase II Trial of Nanoparticle Albumin-Bound Paclitaxel with or without the Anti-Death Receptor 5 Monoclonal Antibody Tigatuzumab in Patients with Triple-Negative Breast Cancer.
Forero-Torres A; Varley KE; Abramson VG; Li Y; Vaklavas C; Lin NU; Liu MC; Rugo HS; Nanda R; Storniolo AM; Traina TA; Patil S; Van Poznak CH; Nangia JR; Irvin WJ; Krontiras H; De Los Santos JF; Haluska P; Grizzle W; Myers RM; Wolff AC;
Clin Cancer Res; 2015 Jun; 21(12):2722-9. PubMed ID: 25779953
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]